Rebecca A Harrison1, Shelli R Kesler2, Jason M Johnson3, Marta Penas-Prado1, Catherine M Sullaway2, Jeffrey S Wefel2,4. 1. Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Section of Neuropsychology, Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
OBJECTIVE: Impaired neurocognitive function (NCF) is a well-established consequence of pediatric medulloblastoma (MB) and its treatments. However, the frequency and features of neurocognitive dysfunction in adult-onset MB patients are largely unknown. METHODS: Adult patients (≥ 18 years) with MB who had received formal neurocognitive evaluation (N = 27) were identified. Demographic, medical, and treatment histories were extracted from the medical record. Lesion properties on MRI were analyzed and used to evaluate lesion-symptom mapping further. Demographically adjusted z-scores were calculated for each neurocognitive test and used to assess impairment frequency. Regression analyses were conducted to identify clinical and paraclinical factors associated with impaired NCF. RESULTS: Mean age of the patient sample was 33 years (SD = 11) at the time of MB diagnosis. Prior therapy included surgical resection (89%), radiation (70%), and chemotherapy (26%). A significant proportion of patients were impaired on tests of verbal learning and memory (32%), executive function (29%), and naming (18%). Age, education, lesion size, time from surgery, and number of chemotherapy cycles had the greatest contribution to test performance in random-forest regression models. CONCLUSION: This study identifies frequent impairment of NCF in adult patients with MB, particularly in the domains of learning and memory and executive function. Neurocognitive impairment is influenced by patients' demographic, disease, and treatment history. Further study is warranted to characterize the clinical impact of adult MB more fully.
OBJECTIVE: Impaired neurocognitive function (NCF) is a well-established consequence of pediatric medulloblastoma (MB) and its treatments. However, the frequency and features of neurocognitive dysfunction in adult-onset MB patients are largely unknown. METHODS: Adult patients (≥ 18 years) with MB who had received formal neurocognitive evaluation (N = 27) were identified. Demographic, medical, and treatment histories were extracted from the medical record. Lesion properties on MRI were analyzed and used to evaluate lesion-symptom mapping further. Demographically adjusted z-scores were calculated for each neurocognitive test and used to assess impairment frequency. Regression analyses were conducted to identify clinical and paraclinical factors associated with impaired NCF. RESULTS: Mean age of the patient sample was 33 years (SD = 11) at the time of MB diagnosis. Prior therapy included surgical resection (89%), radiation (70%), and chemotherapy (26%). A significant proportion of patients were impaired on tests of verbal learning and memory (32%), executive function (29%), and naming (18%). Age, education, lesion size, time from surgery, and number of chemotherapy cycles had the greatest contribution to test performance in random-forest regression models. CONCLUSION: This study identifies frequent impairment of NCF in adult patients with MB, particularly in the domains of learning and memory and executive function. Neurocognitive impairment is influenced by patients' demographic, disease, and treatment history. Further study is warranted to characterize the clinical impact of adult MB more fully.
Authors: Marta Penas-Prado; Brett J Theeler; Brittany Cordeiro; Ira J Dunkel; Peter Hau; Anita Mahajan; Giles W Robinson; Nicole Willmarth; Orwa Aboud; Kenneth Aldape; John A Butman; Amar Gajjar; William Kelly; Ganesh Rao; Margarita Raygada; Christine Siegel; Carlos G Romo; Terri S Armstrong; Mark R Gilbert Journal: Neurooncol Adv Date: 2020-08-17
Authors: Linda Dirven; Ralf Luerding; Dagmar Beier; Elisabeth Bumes; Christiane Reinert; Clemens Seidel; Matteo Mario Bonsanto; Michael Bremer; Stefan Rieken; Stephanie E Combs; Ulrich Herrlinger; Corinna Seliger; Holger Kuntze; Regine Mayer-Steinacker; Annette Dieing; Claudius Bartels; Oliver Schnell; Astrid Weyerbrock; Sabine Seidel; Oliver Grauer; Minou Nadji-Ohl; Frank Paulsen; Michael Weller; Wolfgang Wick; Peter Hau Journal: J Neurooncol Date: 2020-05-04 Impact factor: 4.130
Authors: Nazanin K Majd; Maximilan Mastall; Heather Lin; Seyede Shiva Dibaj; Kenneth R Hess; Ying Yuan; Manuela Martin-Bejarano Garcia; Gregory N Fuller; Kristin D Alfaro; Maria K Gule-Monroe; Jason T Huse; Soumen Khatua; Ganesh Rao; David I Sandberg; Jeffrey S Wefel; Debra N Yeboa; Arnold C Paulino; Susan L McGovern; Wafik Zaky; Anita Mahajan; Dima Suki; Shiao-Pei Weathers; Rebecca A Harriso; John F De Groo; Vinay K Puduvalli; Marta Penas-Prado Journal: Neurooncol Adv Date: 2021-06-22
Authors: Anita Mahajan; Helen Shih; Marta Penas-Prado; Keith Ligon; Kenneth Aldape; Leland S Hu; Ashlee R Loughan; Michael R Basso; Heather E Leeper; Brian V Nahed; Shannon L Stott; Susan Geyer; Caterina Giannini; Evanthia Galanis Journal: Cancers (Basel) Date: 2022-01-14 Impact factor: 6.575